Who Said There's Nothing You Can Do About Early AMD?
As optometrists, a diagnosis of AMD often means the end of the line for us. Late stage AMD needs urgent specialist intervention and earlier forms require the patient to do all the work with nutrition and self-monitoring on Amsler grids. We’re in the middle and keen to help. But what can we offer?
It’s time for us to rethink what’s possible with modern technology. As a chronic progressive disease, AMD can take years to progress to a point where the patient needs to be referred to a hospital. The goal of managing AMD is always to preserve visual function—not to wait until vision has already been lost. Although there is still no cure for AMD, early diagnosis, careful monitoring and proper care could postpone or even prevent visual acuity loss in many of your patients.
In this recorded webinar, Ian Cameron explains the underlying pathology, showing us the importance of early AMD diagnosis with dark adaptation testing, and discusses current treatment options that you can integrate into practice right now for the benefit of your patients.
This is a recording of a webinar that was hosted live as part of our Free Webinar Series. Watching the recording and completing the test is worth 1 CET point.
PRIVACY NOTICE: By completing this free CET course you agree that we will pass your name and email address to MacuLogix who may send you further information on their products and services.
CET Points: 1
CETpoints.com credits: Free
Expiry Date: 31/12/2021
Also accepted by
AMD: Better Outcomes Start With YOU
As AMD becomes a bigger problem in the general patient population, it becomes more important to detect it earlier and treat it appropriately. This lecture will discuss what optometrists can do to help with risk education, prevention, early detection and treatment.
New Treatments for Dry AMD
This lecture will provide some background into age-related macular degeneration (AMD), discuss how the AMD-risk associated mutations affect our immune system and talk about new therapies currently being developed.